The in vitro cultures of erythroid (BFU-E) and megakaryocytic (CFU-Meg) progenitors have been useful diagnostic tools in myeloproliferative disorders (MPD). However, after the discovery of the JAK2V617F mutation, their diagnostic role has been uncertain. In this single-centre retrospective study we analyzed JAK2V617F mutation in 58 ET and 42 PV patients diagnosed according to WHO criteria and compared the results with those of colony forming assays with special emphasis on CFU-Meg growth. 91% of PV and 57% of ET patients had JAK2V617F mutation and they all showed spontaneous BFU-E growth. However, endogenous BFU-E formation was also seen in nine JAK2V617F mutation negative patients displaying also a normal JAK2 exon 12 allele. Endogeneous C...
We studied the implementation of JAK2 mutation analysis in conjunction with the World Health Organis...
Polycythemia vera (PV), essential thrombocythemia (ET) and idiopathic myelofibrosis (IMF) are myelop...
Subclones homozygous for JAK2V617F are more common in polycythemia vera (PV) than essential thromboc...
Myeloproliferative disorders (MPDs) are heterogeneous diseases that occur at the level of a multipot...
SummaryPolycythemia vera (PV), essential thrombocythemia (ET), and myeloid metaplasia with myelofibr...
While about 95% of patients with polycythemia vera (PV) harbor the V617F mutation in JAK2 exon 14, s...
The molecular pathogenesis of chronic myeloproliferative disorders (MPDs) is poorly understood. The ...
BACKGROUND: An acquired V617F mutation in JAK2 occurs in most patients with polycythaemia vera, but ...
The molecular pathogenesis of chronic myeloproliferative disorders (MPDs) is poorly understood. The ...
International audienceLaboratory detection of spontaneous growth of colony-forming unit-megacaryocyt...
Although the chronic myeloproliferative disorders (MPDs) polycythaemia vera (PV) and essential throm...
Polycythemia vera (PV) is a myeloproliferative neoplasm (MPN) associated with somatic mutations of J...
The V617F mutation of JAK2 is the key molecular event in 90% of polycythaemia vera (PV), 50% of esse...
Essential thrombocythemia (ET) is an entity of classic Philadelphia chromosome-negative myeloprolife...
and Jean Luc Villeval have participated in the writing of this review. Myeloproliferative disorders ...
We studied the implementation of JAK2 mutation analysis in conjunction with the World Health Organis...
Polycythemia vera (PV), essential thrombocythemia (ET) and idiopathic myelofibrosis (IMF) are myelop...
Subclones homozygous for JAK2V617F are more common in polycythemia vera (PV) than essential thromboc...
Myeloproliferative disorders (MPDs) are heterogeneous diseases that occur at the level of a multipot...
SummaryPolycythemia vera (PV), essential thrombocythemia (ET), and myeloid metaplasia with myelofibr...
While about 95% of patients with polycythemia vera (PV) harbor the V617F mutation in JAK2 exon 14, s...
The molecular pathogenesis of chronic myeloproliferative disorders (MPDs) is poorly understood. The ...
BACKGROUND: An acquired V617F mutation in JAK2 occurs in most patients with polycythaemia vera, but ...
The molecular pathogenesis of chronic myeloproliferative disorders (MPDs) is poorly understood. The ...
International audienceLaboratory detection of spontaneous growth of colony-forming unit-megacaryocyt...
Although the chronic myeloproliferative disorders (MPDs) polycythaemia vera (PV) and essential throm...
Polycythemia vera (PV) is a myeloproliferative neoplasm (MPN) associated with somatic mutations of J...
The V617F mutation of JAK2 is the key molecular event in 90% of polycythaemia vera (PV), 50% of esse...
Essential thrombocythemia (ET) is an entity of classic Philadelphia chromosome-negative myeloprolife...
and Jean Luc Villeval have participated in the writing of this review. Myeloproliferative disorders ...
We studied the implementation of JAK2 mutation analysis in conjunction with the World Health Organis...
Polycythemia vera (PV), essential thrombocythemia (ET) and idiopathic myelofibrosis (IMF) are myelop...
Subclones homozygous for JAK2V617F are more common in polycythemia vera (PV) than essential thromboc...